Editas Medicine Inc (EDIT) Holdings Trimmed by Benjamin F. Edwards & Company Inc.

Benjamin F. Edwards & Company Inc. lessened its position in shares of Editas Medicine Inc (NASDAQ:EDIT) by 28.0% in the fourth quarter, according to its most recent filing with the SEC. The firm owned 2,443 shares of the company’s stock after selling 950 shares during the quarter. Benjamin F. Edwards & Company Inc.’s holdings in Editas Medicine were worth $56,000 at the end of the most recent quarter.

A number of other large investors have also recently added to or reduced their stakes in the business. Vanguard Group Inc. increased its position in Editas Medicine by 3.9% during the 3rd quarter. Vanguard Group Inc. now owns 3,729,579 shares of the company’s stock valued at $118,675,000 after purchasing an additional 141,609 shares during the period. Vanguard Group Inc increased its position in Editas Medicine by 3.9% during the 3rd quarter. Vanguard Group Inc now owns 3,729,579 shares of the company’s stock valued at $118,675,000 after purchasing an additional 141,609 shares during the period. BlackRock Inc. increased its position in Editas Medicine by 3.9% during the 3rd quarter. BlackRock Inc. now owns 3,589,141 shares of the company’s stock valued at $114,207,000 after purchasing an additional 134,075 shares during the period. ARK Investment Management LLC increased its position in Editas Medicine by 28.1% during the 3rd quarter. ARK Investment Management LLC now owns 2,793,854 shares of the company’s stock valued at $88,900,000 after purchasing an additional 612,282 shares during the period. Finally, Credit Suisse AG increased its position in Editas Medicine by 40.9% during the 3rd quarter. Credit Suisse AG now owns 783,088 shares of the company’s stock valued at $24,918,000 after purchasing an additional 227,266 shares during the period. 69.12% of the stock is owned by institutional investors and hedge funds.

In related news, CFO Andrew A. F. Hack sold 6,895 shares of the stock in a transaction on Monday, February 4th. The stock was sold at an average price of $21.39, for a total value of $147,484.05. Following the transaction, the chief financial officer now directly owns 6,895 shares in the company, valued at approximately $147,484.05. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CTO Vickesh Myer sold 4,000 shares of the stock in a transaction on Tuesday, November 20th. The stock was sold at an average price of $26.50, for a total value of $106,000.00. Following the completion of the transaction, the chief technology officer now owns 2,700 shares in the company, valued at $71,550. The disclosure for this sale can be found here. Insiders have sold a total of 61,179 shares of company stock worth $1,623,659 over the last 90 days. Company insiders own 5.20% of the company’s stock.

Editas Medicine stock opened at $19.95 on Thursday. The company has a market cap of $982.50 million, a price-to-earnings ratio of -6.69 and a beta of 2.56. Editas Medicine Inc has a 52-week low of $17.80 and a 52-week high of $45.02. The company has a current ratio of 13.14, a quick ratio of 13.13 and a debt-to-equity ratio of 0.15.

A number of analysts have weighed in on the stock. ValuEngine downgraded shares of Editas Medicine from a “buy” rating to a “hold” rating in a research report on Friday, December 21st. BidaskClub upgraded Editas Medicine from a “hold” rating to a “buy” rating in a report on Tuesday, December 4th. Zacks Investment Research upgraded Editas Medicine from a “hold” rating to a “buy” rating and set a $32.00 price target on the stock in a report on Tuesday, November 13th. SunTrust Banks restated a “buy” rating on shares of Editas Medicine in a report on Monday, December 31st. Finally, Chardan Capital restated a “buy” rating and set a $55.00 price target on shares of Editas Medicine in a report on Tuesday, January 22nd. Two investment analysts have rated the stock with a sell rating, five have assigned a hold rating and seven have issued a buy rating to the stock. The stock currently has a consensus rating of “Hold” and a consensus target price of $42.50.

TRADEMARK VIOLATION NOTICE: This piece was first posted by Transcript Daily and is the sole property of of Transcript Daily. If you are reading this piece on another website, it was copied illegally and reposted in violation of United States & international trademark & copyright law. The original version of this piece can be accessed at https://transcriptdaily.com/2019/02/14/editas-medicine-inc-edit-holdings-trimmed-by-benjamin-f-edwards-company-inc.html.

Editas Medicine Profile

Editas Medicine, Inc operates as a genome editing company. It focuses on treating patients with genetically defined diseases by correcting their disease causing genes. The company develops a proprietary genome editing platform based on CRISPR technology to target genetically defined diseases with an initial focus on debilitating illnesses where there are no approved treatments.

Further Reading: Investing in Growth Stocks

Want to see what other hedge funds are holding EDIT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Editas Medicine Inc (NASDAQ:EDIT).

Institutional Ownership by Quarter for Editas Medicine (NASDAQ:EDIT)

Receive News & Ratings for Editas Medicine Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Editas Medicine and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply